Showing results (111-120 of 143) with videos related to
Sort By:
Pageof 15
Pathology Oncology Research : POR|March 26, 2017
Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53Tianli He, Jiayou Guo, Hongmei Song, et al.British Journal of Haematology|March 17, 2023
The effect of antinuclear antibody titre and its variation on outcomes in children with primary immune thrombocytopeniaJing Liu, Yuelun Zhang, Zhuo Li, et al.Journal of Leukocyte Biology|August 21, 2020
The role of ubiquitinase in B cell development and functionTong Zhang, Jianxuan Sun, Jiali Cheng, et al.Annals of the Rheumatic Diseases|February 7, 2025
Somatic gain-of-function mutation in TLR7 causes early-onset systemic lupus erythematosusYi Zeng, Panfeng Tao, Jun Wang, et al.Frontiers in Immunology|October 12, 2020
Single-Center Overview of Pediatric Monogenic Autoinflammatory Diseases in the Past Decade: A Summary and BeyondWei Wang, Zhongxun Yu, Lijuan Gou, et al.Genes & Diseases|April 20, 2026
CD14+CXCL10+ monocytes are associated with peripheral immune network alterations in systemic juvenile idiopathic arthritis: From multiple centersQiang Luo, Jun Yang, Haiguo Yu, et al.Journal of Clinical Immunology|January 16, 2020
Juvenile Onset Splenomegaly and Oculopathy Due to Germline Mutation in ALPK1Linqing Zhong, Jun Wang, Wei Wang, et al.Frontiers in Oncology|January 9, 2023
Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132Yezhe Cheng, Xiaoxi Yuan, Qiang Tian, et al.Frontiers in Oncology|January 4, 2024
Corrigendum: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132Yezhe Cheng, Xiaoxi Yuan, Qiang Tian, et al.Frontiers in Microbiology|September 14, 2018
Clinical Performance Evaluation of VersaTrek 528 Blood Culture System in a Chinese Tertiary HospitalPinli Yue, Menglan Zhou, Timothy Kudinha, et al.Pageof 15